Waters Q2 2026 Earnings: Acquisition Doubles Revenue as GAAP Results Turn Negative

Waters Corporation (NYSE: WAT) reported Q2 2026 revenue of $1.645 billion for the quarter ended July 4, up 113% from $771 million, while diluted GAAP EPS swung to a loss of $1.39 from earnings of $2.47. The acquisition of the Biosciences and Diagnostic Solutions businesses contributed $817 million, while organic revenue increased 7% as reported and 9% in constant currency. Adjusted EPS rose 3% to $3.05, and operating cash flow reached $200 million despite the GAAP net loss.

Core earnings results

The 113% reported revenue increase largely reflects the acquired businesses, making organic and prior-year comparable growth more useful measures of underlying performance. Organic revenue reached $828 million, while the acquired operations grew 4% against their prior-year comparable revenue.

Acquisition accounting was the primary reason reported profitability moved in the opposite direction from revenue. Waters recorded $399 million of purchased-intangible amortization and acquisition-related fair-value step-ups, along with restructuring, integration, and transformation expenses.

Business and division performance

Analytical Sciences produced 7% reported growth, including instrument revenue of $240 million, up 5% reported and 8% in constant currency. Chemistry consumables grew at a double-digit constant-currency rate, while both pharmaceutical and academic and government end markets posted low-double-digit growth.

The acquired Biosciences and Diagnostic Solutions operations generated $817 million, $15 million above company guidance and 4% higher on a prior-year comparable basis. Waters attributed the acceleration to commercial execution and operational improvements under its 180-day growth revitalization plan.

The reported 733% increase for the overall Advanced Diagnostics Division is not a like-for-like comparison because the current quarter includes the acquired Diagnostic Solutions business. The separate Diagnostic Solutions and Clinical Business Unit figures provide a clearer view.

Acquisition accounting widened the gap between GAAP and adjusted earnings

Waters reported a $136 million GAAP net loss but $301 million of adjusted net income. The largest adjustment was $399 million related to purchased-intangible amortization and acquisition-related fair-value step-ups, consisting of $155 million in cost-of-revenue adjustments and $244 million of intangible amortization. Other exclusions included $51 million of restructuring and certain other costs, $39 million of acquisition-related costs, and $9 million of ERP and transformation expenses.

Even after those exclusions, adjusted operating margin declined to 25.0% from 29.1%. Adjusted net income rose about 71%, but adjusted EPS increased only 3% because the adjusted diluted share count expanded to 98.5 million from approximately 59.7 million. Net interest expense also increased to $55 million from $10 million.

These figures show that the acquisition substantially increased Waters’ revenue and adjusted profit base, but the benefits translated into much slower per-share earnings growth during the quarter.

Cash flow and balance sheet

Operating cash flow increased to $200 million despite the GAAP net loss. The reconciliation included $301 million of depreciation and amortization and $155 million of noncash acquisition-related fair-value step-ups, partially offset by a $144 million use of cash from changes in operating assets, liabilities, and other items. After capital spending and specified adjustments, adjusted free cash flow was $202 million.

The acquisition also transformed the balance sheet. Debt stood at $5.086 billion on July 4, up from $1.407 billion at the end of 2025, while cash declined from $588 million to $539 million. Goodwill increased to $9.421 billion from $1.340 billion, and intangible assets rose to $8.521 billion from $558 million.

Earnings guidance

Waters raised every component of its full-year 2026 outlook after the better-than-expected quarterly performance and broader end-market recovery. The release did not provide the previous numerical ranges, so the size of each increase cannot be quantified from the available information.

The full-year adjusted EPS range represents 10%-12% reported growth and 12%-14% constant-currency growth. Currency translation is expected to reduce organic reported growth by 0.6 percentage points for the full year and 1.7 points in Q3.

Recent insider transactions

The supplied transaction-level data lists two open-market purchases in March 2026 and eight zero-value stock awards among the latest 10 entries. A separate six-month aggregate in the same source reports no purchases or sales, creating a data inconsistency that prevents broader conclusions about insider activity.

Risks investors should watch

• Integration and comparable-growth risk: The acquired operations contributed nearly half of quarterly revenue. Their prior-year comparable figures reflect how the businesses were historically managed under BD and may not represent their future cost structure under Waters.
• Pressure on per-share profitability: Adjusted operating margin declined by 4.1 percentage points, while the larger share count limited adjusted EPS growth to 3% despite a much larger increase in adjusted net income.
• Higher debt and interest expense: Debt rose to $5.086 billion, and quarterly net interest expense increased to $55 million. These obligations could reduce the cash available for other corporate priorities.
• Foreign-exchange headwinds: Currency reduced Q2 organic growth by two percentage points and is incorporated as a drag in both the full-year and third-quarter outlooks.
• Continued GAAP and non-GAAP divergence: Acquisition-related amortization, restructuring, and integration costs produced a substantial gap between reported and adjusted earnings, and Waters said the timing and size of future adjustments are difficult to forecast.

Summary

Waters’ second-quarter results show a company operating at a much larger scale following the Biosciences and Diagnostic Solutions acquisition. Organic growth broadened across instruments, consumables, and end markets, while the acquired businesses reached mid-single-digit comparable growth. The main issues to monitor are whether Waters can convert its expanded revenue base into stronger margins and per-share earnings, execute the integration, manage higher debt, and deliver the raised full-year outlook.